Heather Dountas, PA
Physician Assistant · Albuquerque, NMNPI 1407889074
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,387, 4.9 times the $284 reported in 2022. Among physician assistant clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$610
- Novo Nordisk$537
- Pfizer$362
- Lilly USA, LLC$301
- AstraZeneca$249
- Otsuka America Pharmaceutical, Inc.$193
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,58299%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $610 |
| Novo Nordisk | 37 | $537 |
| Pfizer | 20 | $362 |
| Lilly USA, LLC | 15 | $301 |
| AstraZeneca | 15 | $249 |
| Otsuka America Pharmaceutical, Inc. | 10 | $193 |
| Astellas Pharma US Inc | 7 | $154 |
| Boehringer Ingelheim | 7 | $145 |
| GSK | 5 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $90 |
| Abbott | 4 | $89 |
| Sanofi Pasteur Inc. | 3 | $78 |
| Mylan Specialty L.p. | 3 | $75 |
| Amgen | 3 | $69 |
| Exact Sciences | 4 | $67 |
| Baxter Healthcare | 2 | $66 |
| Lundbeck LLC | 2 | $48 |
| Viatris Specialty LLC | 2 | $42 |
| Bardy Diagnostics, Inc. | 1 | $42 |
| Novartis | 3 | $41 |
| Bayer | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Vertex | 1 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Seqirus USA Inc | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Exeltis, USA Inc. | 1 | $16 |
| Angiodynamics, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Merck | 1 | $14 |
How this compares
$3,620 in reported general payments places this provider in the 95th percentile of 635 physician assistant providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 53 | $61,147 |
| JardianceEmpagliflozin | 35 | $57,982 |
| OzempicSemaglutide | 27 | $37,377 |
| EliquisApixaban | 36 | $36,775 |
| FarxigaDapagliflozin Propanediol | 30 | $31,651 |
| RexultiBrexpiprazole | 15 | $24,332 |
| TrulicityDulaglutide | 18 | $22,786 |
| WegovySemaglutide | 16 | $20,797 |
| XareltoRivaroxaban | 14 | $18,871 |
| MyrbetriqMirabegron | 11 | $13,096 |
| Spiriva RespimatTiotropium Bromide | 12 | $12,280 |
| Bydureon BciseExenatide Microspheres | 11 | $8,308 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,631 |
| Fluticasone Propionate HfaFluticasone Propionate | 19 | $5,574 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $301 | $83,93371 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $145 | $70,26247 claims |
| Novo NordiskOzempic, Wegovy | $537 | $58,17443 claims |
| AstraZenecaFarxiga, Symbicort | $249 | $38,28148 claims |
| PfizerEliquis | $362 | $36,77536 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $193 | $24,33215 claims |
| Astellas Pharma US IncMyrbetriq | $154 | $13,09611 claims |
| GSKAnoro Ellipta | $90 | $5,40712 claims |
| AbbVieSynthroid | $610 | $1,15514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 635 physician assistant providers in New Mexico.
Other physician assistant in Albuquerque
- Leigh HigginsAlbuquerque$10K
- Maria AbeytaAlbuquerque$8K
- Kari LavigneAlbuquerque$8K
- Elizabeth BelitzAlbuquerque$8K
- Desiree BarelaAlbuquerque$6K
- Stephanie BeyesAlbuquerque$5K
- Stephanie GonzalesAlbuquerque$5K
- Miquela WiegelAlbuquerque$5K
- Gabriela PobarAlbuquerque$5K
- Jacklyn ChavezAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.